๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Global status of clinical photodynamic therapy: The registration process for a new therapy

โœ Scribed by Dr. Stuart L. Marcus; Margaret H. Dugan

Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
809 KB
Volume
12
Category
Article
ISSN
0196-8092

No coin nor oath required. For personal study only.

โœฆ Synopsis

The clinical use of photodynamic therapy (PDT) has been ongoing for over a decade. However, attempts to apply for approval of the therapy from boards of health for general use began only in 1989. The unique nature of PDT and the resultant changes in the normal drug registration process, as well as steps which are being taken to approve PDT for the treatment of endobronchial lung cancer, superficial bladder cancer and esophageal cancer are described. The current clinical status of PDT in these indications is also reviewed.

๐Ÿ“œ SIMILAR VOLUMES

A first trial in the clinical applicatio
A first trial in the clinical application of photodynamic therapy for the prevention of restenosis after coronary-stent placement
โœ Mikio Usui; Manabu Miyagi; Shinya Fukasawa; Takeshi Hara; Naoya Ueyama; Hitoshi ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 153 KB

## Abstract ## Background and Objectives The aim of this clinical study was to evaluate the safety of local delivery of a photosensitizer followed by photodynamic therapy (PDT), to determine its effectiveness in reducing inโ€stent restenosis. ## Study Design/Patients and Methods Porfimer sodium w

Comparative biodistribution of meta-Tetr
Comparative biodistribution of meta-Tetra (Hydroxyphenyl) chlorin in multiple species: Clinical implications for photodynamic therapy
โœ Ronn, Avigdor M.; Batti, James; Lee, Catherine J.; Yoo, Don; Siegel, Michelle E. ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 143 KB ๐Ÿ‘ 1 views

## Background and objective: To optimize photodynamic therapy, it is necessary to know the distribution of photosensitizer in normal tissue as well as tumors and to know how well animal models match human. this study measured the biodistribution of meta-tetra(hydroxyphenyl) chlorin (mthpc) in three

Clinical and research applications of ph
Clinical and research applications of photodynamic therapy in dermatology: Experience of the scottish PDT centre
โœ H. Moseley; S. Ibbotson; J. Woods; L. Brancaleon; A. Lesar; C. Goodman; J. Fergu ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 339 KB

## Abstract ## Background and Objectives The Scottish PDT Centre has carried out 3,442 treatments on 762 patients with superficial skin lesions, especially superficial basal cell carcinoma (sBCC), Bowen's disease (BD) and actinic keratosis (AK). ## Study Design Materials and Methods The article

Comparison of 5-aminolaevulinic acid and
Comparison of 5-aminolaevulinic acid and porphyrin photosensitization for photodynamic therapy of malignant bronchial stenosis: A clinical pilot study
โœ Alfred Maier; Florian Tomaselli; V. Matzi; M. Woltsche; Udo Anegg; B. Fell; Pete ๐Ÿ“‚ Article ๐Ÿ“… 2002 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 152 KB

## Abstract ## Background and Objectives Photosan^ยฎ^, a mixture of porphyrin oligomers as sensitizer for photodynamic therapy (PDT), carry the risk of prolonged photosensitivity of the skin. New sensitizer such as 5โ€aminolaevulinic acid (ALA) with low rates of skin phototoxicity appear to be promi

Silicon phthalocyanine (pc 4) photodynam
Silicon phthalocyanine (pc 4) photodynamic therapy is a safe modality for cutaneous neoplasms: results of a phase 1 clinical trial
โœ Elma D. Baron; Christi L. Malbasa; Diana Santo-Domingo; Pingfu Fu; Janine D. Mil ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 212 KB

Background: Photodynamic therapy (PDT) is a non-invasive treatment for non-melanoma skin cancer. However, PDT systems currently used clinically have limitations such as painand superficial tissue penetration. The silicon phthalocyanine Pc 4 is a second-generation photosensitizer with peak absorption